Dimerix Bioscience

chronic kidney disease money
Biotech

Dimerix buys Mission’s kidney disease prospect in $292M deal

Dimerix is Mission paying $5 million upfront and committing up to $287 million in milestones for the phase 2-ready acute kidney injury asset.
Nick Paul Taylor Jul 17, 2026 5:00am
MA strategy deal block push come together form

Amicus pays Dimerix $30M for late-phase rare kidney disease drug

May 1, 2025 10:59am